- 599
From what I found, there's nothing official about requirements. I have seen a lot more plans with specialty tiers for these drugs however.
To mitigate the cost to patients and encourage treatment, many specialty pharmaceutical manufacturers offer assistance programs to patients. These programs provide coupons to patients for some, or all, of the amount of cost sharing. In the case of Medicare, where such assistance is not allowed under federal law, some manufacturers provide grants to independent nonprofit organizations, which in turn are able to reimburse patients a portion of their share of the costs of medicines.
These discount programs have been criticized by payers and PBMs because they reduce the incentives that are embedded in traditional benefit designs and may lead to overuse. Therefore, even though copayment assistance programs may make a particular product more affordable for an individual patient, some contend that they increase the overall costs to the plan and all members covered under the plan by encouraging the product's use. Manufacturers and patient advocates defend these discount programs, arguing that the cost-reduction incentives of traditional benefit design should not be applied to specialty products because of the seriousness of the diseases they treat and the small patient populations involved. In addition, by making these high-cost therapies more affordable to patients, coupons and copayment assistance can help reduce nonadherence and its consequences, such as emergency department visits and hospitalizations.